Published September 2003 | Version v1
Journal article

Strontium - 89 combined with technetium - 99 methylenediphosphonate for the treatment of malignant bony metastasis in the patients with advanced prostate cancer

  • 1. Department of Urology, the Second Hospital Affiliated to Suzhou University, Suzhou (China)

Description

Objective: This work was done to evaluate the effectiveness and side effects of the therapy of radioactive nuclide strontium - 89 (89Sr) and technetium - 99 methylenediphosphonate (99Tc - MDP) for malignant bony metastasis in the patients with advanced prostate cancer. Methods: Twenty patients with skeletal metastasis received this treatment of 89Sr and 99Tc - MDP. The patients were observed and followed up with respect to pain control, lesion improvement and side effects. Results: The overall effective rate of pain control was 86.66%. The lesion in eight patients as assessed by SPECT imaging, was improved. The main side effect was the mild recoverable descent of leukocytes and thrombocytes. Conclusion: The treatment of 89Sr and 99Tc - MDP is very useful for malignant bony metastasis in patients with advanced prostate cancer, especially for metastatic bone pain

Additional details

Publishing Information

Journal Title
Acta Academiae Medicinae Suzhou
Journal Volume
23
Journal Issue
5
Journal Page Range
p. 553-554, 603
ISSN
1000-5749